title: Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?
abstract: Chemotherapy regimens may have differential efficacy by histology in nonsmall cell lung cancer (NSCLC). We examined the impact of histology on survival of patients (N = 2,644) with stage IIIB/IV NSCLC who received first-line cisplatin/carboplatin plus gemcitabine (C/C+G) and cisplatin/carboplatin plus a taxane (C/C+T) identified retrospectively in the SEER cancer registry (1997-2002). Patients with squamous and nonsquamous cell carcinoma survived 8.5 months and 8.1 months, respectively (P = .018). No statistically significant difference was observed in survival between C/C+G and C/C+T in both histologies. Adjusting for clinical and demographic characteristics, the effect of treatment regimen on survival did not differ by histology (P for interaction = .257). There was no statistically significant difference in hazard of death by histology in both groups. These results contrast the predictive role of histology and improved survival outcomes observed for cisplatin-pemetrexed regimens in advanced nonsquamous NSCLC.
authors.affiliation: i3 Innovus, Medford, MA 02155, USA.
authors.forename: Karen M
authors.initials: KM
authors.lastname: Clements
authors.forename: Gerson
authors.initials: G
authors.lastname: Peltz
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Faries
authors.forename: Kathleen
authors.initials: K
authors.lastname: Lang
authors.forename: Joshua
authors.initials: J
authors.lastname: Nyambose
authors.forename: Craig C
authors.initials: CC
authors.lastname: Earle
authors.forename: Katherine P
authors.initials: KP
authors.lastname: Sugarman
authors.forename: Douglas C A
authors.initials: DC
authors.lastname: Taylor
authors.forename: David
authors.initials: D
authors.lastname: Thompson
authors.forename: Martin D
authors.initials: MD
authors.lastname: Marciniak